Empowering women to live healthier lives!
Text size
Email
Print
Bosulif Approved for Rare Leukemia
WEDNESDAY, Sept. 5 (HealthDay News) -- Bosulif (bosutinib) has been approved by the U.S. Food and Drug Administration to treat chronic myelogenous leukemia (CML), a cancer of the blood and bone marrow that primarily affects older people, the agency said in a news release.
Some 5,430 people are expected to be diagnosed this year with the disease, which primarily is caused by a genetic mutation called the Philadelphia chromosome, the FDA said. This abnormality causes a person's bone marrow to produce an enzyme that triggers development of abnormal white blood cells known as granulocytes. The new drug works to block the effects of this enzyme.
Bosulif was evaluated in a clinical trial that included 546 adults with CML. The drug's most common side effects included diarrhea, nausea, low blood platelets, abdominal pain, rash, anemia, fever and fatigue.
The drug is marketed by Pfizer, based in New York City.
More information
To learn more about this approval, visit the FDA.
Copyright © 2012 HealthDay. All rights reserved.
HealthDay news articles are derived from various sources and do not reflect federal policy. Womenshealth.gov does not endorse opinions, products, or services that may appear in news stories.
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.200 Independence Avenue, S.W. • Washington, DC 20201
202-690-7650 • Monday through Friday, 9 a.m. to 5 p.m. EST (closed on federal holidays).
womenshealth.gov
A federal government website managed by the Office on Women's Health in the Office of the Assistant Secretary for Health at the U.S. Department of Health and Human Services.
200 Independence Avenue, S.W. • Washington, DC 20201